Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 64
Filter
1.
Clin Genet ; 89(6): 724-7, 2016 06.
Article in English | MEDLINE | ID: mdl-26757254

ABSTRACT

Lissencephaly is a phenotypically and genetically heterogeneous group of cortical brain malformations due to abnormal neuronal migration. The identification of many causative genes has increased the understanding of normal brain development. A consanguineous family was ascertained with three siblings affected by a severe prenatal neurodevelopmental disorder characterised by fronto-parietal pachygyria, agenesis of the corpus callosum and progressive severe microcephaly. Autozygosity mapping and exome sequencing identified a homozygous novel single base pair deletion, c.1197delT in DMRTA2, predicted to result in a frameshift variant p.(Pro400Leufs*33). DMRTA2 encodes doublesex and mab-3-related transcription factor a2, a transcription factor key to the development of the dorsal telencephalon. Data from murine and zebrafish knockout models are consistent with the variant of DMTRA2 (DMRT5) as responsible for the cortical brain phenotype. Our study suggests that loss of function of DMRTA2 leads to a novel disorder of cortical development.


Subject(s)
Cerebral Cortex/abnormalities , Genetic Predisposition to Disease/genetics , Lissencephaly/genetics , Mutation , Animals , Base Sequence , Consanguinity , Disease Models, Animal , Exome/genetics , Family Health , Female , Humans , Male , Mice , Pedigree , Sequence Analysis, DNA/methods , Siblings , Transcription Factors , Xenopus/genetics , Zebrafish/genetics
2.
Nano Lett ; 14(2): 774-82, 2014 Feb 12.
Article in English | MEDLINE | ID: mdl-24372258

ABSTRACT

A liquid metal filament supported on a dielectric substrate was directed to fragment into an ordered, mesoscale particle ensemble. Imposing an undulated surface perturbation on the filament forced the development of a single unstable mode from the otherwise disperse, multimodal Rayleigh-Plateau instability. The imposed mode paved the way for a hierarchical spatial fragmentation of the filament into particles, previously seen only at much larger scales. Ultimately, nanoparticle radius control is demonstrated using a micrometer scale switch.

3.
Opt Lett ; 39(19): 5693-6, 2014 Oct 01.
Article in English | MEDLINE | ID: mdl-25360961

ABSTRACT

In recent papers, it has been theoretically shown that by using dual-period wire gratings, it is possible to control the relative efficiencies of the diffracted orders, regardless of the wires' material, incident polarization and wavelength. In this Letter, we experimentally demonstrate, for the first time, that by appropriately choosing the geometrical parameters of a nanometric periodic structure, it is possible to control the optical response in the visible range. We show examples of nanostructures designed to cancel out or to intensify a particular diffraction order. Such nanostructures allow a broad control over the directionality and the intensity of the diffracted light, which makes them useful for applications such as highly directional optical nanoantennas and photonic multiplexers.

4.
Nanotechnology ; 23(14): 145301, 2012 Apr 13.
Article in English | MEDLINE | ID: mdl-22433664

ABSTRACT

High resolution and isolated scanning probe microscopy (SPM) is in demand for continued development of energy storage and conversion systems involving chemical reactions at the nanoscale as well as an improved understanding of biological systems. Carbon nanotubes (CNTs) have large aspect ratios and, if leveraged properly, can be used to develop high resolution SPM probes. Isolation of SPM probes can be achieved by depositing a dielectric film and selectively etching at the apex of the probe. In this paper the fabrication of a high resolution and isolated SPM tip is demonstrated using electron beam induced etching of a dielectric film deposited onto an SPM tip with an attached CNT at the apex.


Subject(s)
Microscopy, Scanning Probe , Molecular Probes/chemistry , Nanotubes, Carbon/chemistry , Nanotubes, Carbon/ultrastructure , Electroplating , Gold/chemistry , Microscopy, Electron, Scanning , Molecular Probes/chemical synthesis , Nanotechnology/methods , Solutions
5.
Langmuir ; 27(21): 13314-23, 2011 Nov 01.
Article in English | MEDLINE | ID: mdl-21916507

ABSTRACT

Nanoscale copper rings of different radii, thicknesses, and widths were synthesized on silicon dioxide thin films and were subsequently liquefied via a nanosecond pulse laser treatment. During the nanoscale liquid lifetimes, the rings experience competing retraction dynamics and thin film and/or Rayleigh-Plateau types of instabilities, which lead to arrays of ordered nanodroplets. Surprisingly, the results are significantly different from those of similar experiments carried out on a Si surface. We use hydrodynamic simulations to elucidate how the different liquid/solid interactions control the different instability mechanisms in the present problem.

6.
Science ; 248(4953): 358-61, 1990 Apr 20.
Article in English | MEDLINE | ID: mdl-2183354

ABSTRACT

A series of peptide derivatives based on the transition-state mimetic concept has been designed that inhibit the proteinase from the human immunodeficiency virus (HIV). The more active compounds inhibit both HIV-1 and HIV-2 proteinases in the nanomolar range with little effect at 10 micromolar against the structurally related human aspartic proteinases. Proteolytic cleavage of the HIV-1 gag polyprotein (p55) to the viral structural protein p24 was inhibited in chronically infected CEM cells. Antiviral activity was observed in the nanomolar range (with one compound active below 10 nanomolar) in three different cell systems, as assessed by p24 antigen and syncytium formation. Cytotoxicity was not detected at 10 and 5 micromolar in C8166 and JM cells, respectively, indicating a high therapeutic index for this new class of HIV proteinase inhibitors.


Subject(s)
Antiviral Agents , Endopeptidases/metabolism , Gene Products, pol/metabolism , HIV-1/enzymology , HIV-2/enzymology , Peptides/pharmacology , Protease Inhibitors/pharmacology , Amino Acid Sequence , Cell Line , Drug Design , Gene Products, gag/metabolism , HIV Protease , HIV-1/drug effects , Molecular Sequence Data , Molecular Structure , Structure-Activity Relationship
7.
Mol Cell Biol ; 15(8): 3969-78, 1995 Aug.
Article in English | MEDLINE | ID: mdl-7623793

ABSTRACT

Somatic cell hybrids generated from transgenic mouse cells have been used to examine the developmental regulation of human gamma-to-beta-globin gene switching. In hybrids between mouse erythroleukemia (MEL) cells and transgenic erythroblasts taken at various stages of development, there was regulated expression of the human fetal gamma and adult beta genes, reproducing the in vivo pattern prior to fusion. Hybrids formed from embryonic blood cells produced predominantly gamma mRNA, whereas beta gene expression was observed in adult hybrids and a complete range of intermediate patterns was found in fetal liver hybrids. The adult environment of the MEL cells, therefore, did not appear to influence selective transcription from this gene complex. Irradiation of the embryonic erythroid cells prior to fusion resulted in hybrids containing only small fragments of donor chromosomes, but the pattern of gene expression did not differ from that of unirradiated hybrids. This finding suggests that continued expression of trans-acting factors from the donor erythroblasts is not necessary for continued expression of the human gamma gene in MEL cells. These results contrast with the lack of developmental regulation of the cluster after transfection of naked DNA into MEL cells and suggest that epigenetic processes established during normal development result in the gene cluster adopting a developmental stage-specific, stable conformation which is maintained through multiple rounds of replication and transcription in the MEL cell hybrids. On prolonged culture, hybrids that initially expressed only the gamma transgene switched to beta gene expression. The time period of switching, from approximately 10 to > 40 weeks, was similar to that seen previously in human fetal erythroblast x MEL cell hybrids but in this case bore no relationship to the time of in vivo switching. It seems unlikely, therefore, that switching in these hybrids is regulated by a developmental clock.


Subject(s)
Embryo, Mammalian/metabolism , Erythroblasts/metabolism , Gene Expression Regulation, Developmental , Genes, Switch/genetics , Globins/genetics , Animals , Blood , Embryo, Mammalian/cytology , Erythroblasts/radiation effects , Fetal Blood/cytology , Gamma Rays , Globins/biosynthesis , Humans , Hybrid Cells , Karyotyping , Liver/cytology , Liver/embryology , Mice , Mice, Inbred C57BL , Mice, Inbred CBA , Mice, Transgenic , Multigene Family/genetics , RNA, Messenger/biosynthesis , RNA, Messenger/genetics , Recombinant Proteins/biosynthesis , Spleen/cytology , Spleen/embryology
8.
AIDS ; 9 Suppl 2: 27-S32, 1995 Dec.
Article in English | MEDLINE | ID: mdl-8775804

ABSTRACT

AIM: To review available drug-resistance patterns of HIV proteinase inhibitors, in particular saquinavir (formerly known as Ro 31-8959), focusing on the implications for disease management. RESULTS: Reduced sensitivity to saquinavir appears to develop slowly and at low frequency even during prolonged therapy, with an incidence of approximately 45% in 1 year of monotherapy. This reduced sensitivity is consistently associated with the presence of two independent mutations in the proteinase gene, glycine-->valine at position 48 and leucine-->methionine at position 90, with the latter predominating in vivo. Double mutants are rare, with a reported incidence of approximately 2% to date. There is no evidence that the incidence of resistance to saquinavir is increased at doses two to four times higher than those used in clinical studies. In fact, the opposite may be true. The incidence of zidovudine resistance is decreased during combination therapy with saquinavir compared to that during monotherapy, while the incidence of resistance to saquinavir is decreased by combination with zidovudine and zalcitabine. CROSS-RESISTANCE: According to the available genotype data, treatment with saquinavir is not associated with mutations at codons 46, 63 and 82, which are reported to induce cross-resistance to many other proteinase inhibitors. Saquinavir may be associated with mutations at position 84, but very rarely. CONCLUSIONS: Saquinavir appears to be well-suited to first-line monotherapy or combination therapy without prejudicing subsequent or concurrent use of other proteinase inhibitors not affected by mutations at codons 48 and 90.


Subject(s)
Acquired Immunodeficiency Syndrome/drug therapy , Antiviral Agents/therapeutic use , HIV Protease Inhibitors/therapeutic use , Isoquinolines/therapeutic use , Quinolines/therapeutic use , Drug Resistance, Microbial , HIV Protease/genetics , Humans , Saquinavir
9.
Gene ; 101(1): 89-96, 1991 May 15.
Article in English | MEDLINE | ID: mdl-1676389

ABSTRACT

The Saccharomyces cerevisiae glycerol-3-phosphate dehydrogenase (GUT2) promoter and part of the protein-coding region have been isolated on a 6.3-kb genomic DNA fragment. Nucleotide sequence analysis shows that the promoter has many structural features in common with yeast glycolytic enzyme promoters. Chromosomal mapping indicates that this genomic fragment is located on chromosome XII. The GUT2 promoter has been used to construct a recombinant human albumin (reHA) secretion vector; yeast transformed with this vector secrete reHA into the culture supernatant.


Subject(s)
Cloning, Molecular , Genes, Fungal , Glycerolphosphate Dehydrogenase/genetics , Promoter Regions, Genetic/genetics , Saccharomyces cerevisiae/genetics , Amino Acid Sequence , Base Sequence , Blotting, Northern , Molecular Sequence Data , Open Reading Frames/genetics , Plasmids , Polymorphism, Restriction Fragment Length , Promoter Regions, Genetic/physiology , RNA, Transfer, Ala/genetics , Recombinant Proteins/metabolism , Restriction Mapping , Sequence Homology, Nucleic Acid , Serum Albumin/metabolism , Transformation, Genetic
10.
Gene ; 33(2): 215-26, 1985.
Article in English | MEDLINE | ID: mdl-3888784

ABSTRACT

The 'promoter' fragment from the yeast phosphoglycerate kinase (PGK) gene has been used to direct the expression of human interferon-alpha-2 (IFN alpha 2) on a high-copy-number plasmid in yeast. The yields of IFN alpha 2 are only 1-3% of yeast total protein, whereas the maximum yield of PGK produced by the PGK gene on a high-copy-number plasmid is at least 50%. IFN alpha 2 is turned over more rapidly than PGK but in addition a major reason for the relatively low level of IFN alpha 2 is that IFN-specific RNA levels are much lower. This does not reflect differences in plasmid copy number or integrity, or differences in the 5' and 3' untranslated regions of the transcripts or DNA flanking regions. It appears that the presence of heterologous coding sequences, or the absence of specific yeast sequences causes a reduction in heterologous RNA levels in yeast.


Subject(s)
Gene Expression Regulation , Interferon Type I/genetics , Saccharomyces cerevisiae/genetics , Cloning, Molecular , DNA Replication , DNA, Recombinant , Genetic Engineering , Phosphoglycerate Kinase/genetics , Plasmids , Promoter Regions, Genetic , RNA, Messenger/genetics
11.
Gene ; 24(1): 1-14, 1983 Sep.
Article in English | MEDLINE | ID: mdl-6313478

ABSTRACT

We have constructed a high-efficiency expression vector to direct the synthesis of heterologous polypeptides in yeast. The vector is termed a sandwich expression vector as the heterologous gene is inserted between the 5' and 3' control regions of the efficiently expressed yeast PGK gene. We have used this vector to direct the expression of three derivatives of the calf chymosin cDNA gene; preprochymosin, prochymosin and chymosin. Prochymosin is synthesised to at least 5% of total yeast-cell protein and furthermore, it can be readily activated to produce an enzyme which has milk-clotting activity.


Subject(s)
Chymosin/genetics , Saccharomyces cerevisiae/genetics , Animals , Chymosin/metabolism , Enzyme Activation , Genetic Vectors , Milk/metabolism , Molecular Weight , Phosphoglycerate Kinase/genetics , Plasmids , Protein Precursors/genetics , RNA, Messenger/genetics
12.
FEBS Lett ; 390(2): 187-90, 1996 Jul 22.
Article in English | MEDLINE | ID: mdl-8706856

ABSTRACT

Increased elastinolytic activity has been correlated with the degree of lung damage occurring in a variety of lung diseases including cystic fibrosis; serine proteinase inhibitors are currently on trial for the treatment of some lung disorders. However, human lung lavage cells also secrete metallo-dependent elastases. Here we show, for the first time, that whilst these are readily inhibited by EDTA, inhibition of serine elastases using serpins (serine proteinase inhibitors) is not always possible. This may reflect inactivation of serpins by uninhibited metalloproteinases and oxidants in a low protein milieu. Thus, the therapeutic inhibition of excessive elastinolytic activity may require a combination of inhibitors to work efficiently.


Subject(s)
Lung/enzymology , Pancreatic Elastase/antagonists & inhibitors , Adult , Aged , Bronchoalveolar Lavage Fluid/cytology , Culture Media, Conditioned , Edetic Acid/pharmacology , Enzyme Inhibitors/pharmacology , Humans , In Vitro Techniques , Leukocyte Elastase , Lung/cytology , Lung Diseases/drug therapy , Lung Diseases/enzymology , Lymphocytes/enzymology , Macrophages, Alveolar/enzymology , Middle Aged , Neutrophils/enzymology , Serpins/pharmacology , alpha 1-Antitrypsin/pharmacology
13.
FEBS Lett ; 183(2): 201-5, 1985 Apr 22.
Article in English | MEDLINE | ID: mdl-3845890

ABSTRACT

Studies of the inhibition of elastases at a molecular level have resulted in the identification of protected dipeptides which are reversible and highly specific inhibitors of human leucocyte elastase (HLE). These have been further developed by increasing their hydrophilicity and potency to give a new family of elastase inhibitors, typically N alpha-(1-adamantanesulphonyl)-N epsilon-(4-carboxybenzoyl)-L-lysyl-L-alanyl-L-valinal. These compounds are active in pharmacological models designed to detect compounds of potential therapeutic value in the treatment of emphysema.


Subject(s)
Adamantane/analogs & derivatives , Enzyme Inhibitors/pharmacology , Leukocytes/enzymology , Oligopeptides , Pancreatic Elastase/antagonists & inhibitors , Adamantane/pharmacology , Animals , Binding Sites , Cricetinae , Emphysema/drug therapy , Humans , Lung/drug effects , Models, Molecular , Substrate Specificity
14.
J Interferon Cytokine Res ; 19(10): 1145-52, 1999 Oct.
Article in English | MEDLINE | ID: mdl-10547154

ABSTRACT

Biologically active interleukin-12 (IL-12), comprising a 40 kDa subunit (p40) covalently linked to a 35 kDa subunit (p35), is produced in response to a range of infectious stimuli. Here, we demonstrate that mice deficient in either IL-12 p40 (p40-/-) or IL-12 p35 (p35-/-) are susceptible to murine cytomegalovirus (MCMV) infection in terms of survival (Balb/c p35-/-) and viral clearance (Balb/c p35-/- and Balb/c p40-/-), and this susceptibility may be correlated to a deficiency in serum interferon-gamma (IFN-gamma) levels. These data support a role for endogenous IL-12 in controlling MCMV infection. The IL-12 p40 subunit is produced in excess of IL-12 p35, and to date the function of the excess endogenous p40 has been assumed to be one of IL-12 antagonism, as demonstrated by experiments with exogenous p40 both in vivo and in vitro. We show that Balb/c p35-/- alone are significantly compromised in survival of a sublethal infection and in clearance of virus from the spleen. These mice produce a very early IFN-gamma spike (8 h after infection) and an aberrant tumor necrosis factor-alpha (TNF-alpha) spike (day 2 after infection). MCMV infection has revealed an altered Balb/c p35-/- phenotype compared with Balb/c p40-/-, and this indicates that endogenous p40 may have an activity independent of and additional to IL-12 antagonism in vivo.


Subject(s)
Cytomegalovirus Infections/physiopathology , Immunity, Innate , Interleukin-12/physiology , Peptide Fragments/physiology , Animals , Cytomegalovirus Infections/immunology , Interleukin-12/chemistry , Metabolic Clearance Rate , Mice , Mice, Inbred BALB C , Survival Rate , Up-Regulation
15.
J Med Chem ; 33(8): 2137-45, 1990 Aug.
Article in English | MEDLINE | ID: mdl-2165161

ABSTRACT

A range of 2'-fluoro and 2',3'-difluoro analogues of pyrimidine deoxyribonucleosides have been synthesized and evaluated against human immunodeficiency virus (HIV-1) in a human lymphoblastoid cell line. Among these compounds, 1-(2,3-dideoxy-2-fluoro-beta-D-threopentofuranosyl)cytosine (12), 2',3'-didehydro-2',3'-dideoxy-2'-fluorocytidine (35), 1-(2,3-dideoxy-2,3-difluoro-beta-D-arabinofuranosyl)cytosine (41), and 3'-deoxy-2',3'-didehydro-2'-fluorothymidine (45) were found to have significant antiviral activity, with IC50 values of 0.65, 10, 10, and 100 microM, respectively. The structure-activity relationships are discussed.


Subject(s)
Antiviral Agents/pharmacology , Deoxyribonucleosides/pharmacology , Fluorine , HIV-1/drug effects , Pyrimidine Nucleosides/pharmacology , Antiviral Agents/chemical synthesis , Cell Line , Cell Survival/drug effects , Chemical Phenomena , Chemistry , Deoxyribonucleosides/chemical synthesis , Dideoxynucleosides/chemical synthesis , Dideoxynucleosides/pharmacology , Humans , Lymphocytes/drug effects , Molecular Structure , Pyrimidine Nucleosides/chemical synthesis , Structure-Activity Relationship , Zalcitabine/analogs & derivatives , Zalcitabine/chemical synthesis , Zalcitabine/pharmacology
16.
Clin Pharmacokinet ; 25(2): 136-44, 1993 Aug.
Article in English | MEDLINE | ID: mdl-8403737

ABSTRACT

The influence of aging on the metabolism of phenazone (antipyrine), and the relationship between the formation of 3 phenazone metabolites and the metabolic clearance of theophylline in healthy and frail elderly women, were examined. Whereas the elimination half-life did not change, clearance of phenazone decreased by about 50% with age in healthy women receiving phenazone without theophylline. However, the summation of the urinary recovery of phenazone and the measured metabolites, expressed as percentage of the phenazone dose, was lower in the healthy elderly (37 +/- 9% vs 74 +/- 15%). In both healthy and frail females the clearance of formation of 4-hydroxy-phenazone and the metabolic clearance of theophylline correlated strongly (r = 0.93 and 0.90, respectively). In non-healthy elderly females, strong correlations were also observed between the other metabolic pathways of phenazone and the metabolic clearance of theophylline. Coadministration of theophylline in the elderly increased the percentage of the phenazone dose excreted as the measured metabolites. A considerably higher interindividual variability in the disposition of phenazone and theophylline was observed in the frail elderly women. This high degree of variability in drug metabolism may be one of the explanations for the problems often occurring after drug prescription in the elderly.


Subject(s)
Antipyrine/pharmacokinetics , Frail Elderly , Theophylline/pharmacokinetics , Adult , Aged , Aged, 80 and over , Aging/metabolism , Antipyrine/blood , Antipyrine/urine , Chromatography, High Pressure Liquid , Female , Half-Life , Health Status , Humans , Theophylline/blood , Theophylline/urine
17.
J Endocrinol ; 126(3): 507-13, 1990 Sep.
Article in English | MEDLINE | ID: mdl-2212938

ABSTRACT

Healthy men and women aged 19-38 or 67-83, in whom endogenous ACTH secretion was suppressed with dexamethasone, were given successive injections of 60 ng, 150 ng and 250 micrograms ACTH(1-24) at hourly intervals, and blood samples for measurement of plasma cortisol were taken every 10 min. The response to each injection was taken as the increase in cortisol concentration 20 min later, when there was a peak with the lower doses, with allowance for disappearance of cortisol produced after the previous injection. On average, the responses to 60 and 150 ng ACTH were about 0.4 and 0.7 respectively of the response to 250 micrograms. There were no consistent effects of age or sex on any index of adrenocortical sensitivity or responsiveness, but some groups showed isolated differences from both their age- and sex-matched counterparts: the response to 60 ng ACTH was low in young men, maximal responsiveness was low in elderly men and the slope of the dose-response curve was high in elderly women. In most of the elderly subjects, plasma ACTH was determined separately under normal conditions. It was negatively correlated with the cortisol responses to 60 and 150 ng ACTH, suggesting that differences in adrenal sensitivity between subjects contribute to the variability of plasma ACTH.


Subject(s)
Adrenal Glands/drug effects , Aging/metabolism , Cosyntropin/pharmacology , Hydrocortisone/metabolism , Adrenal Glands/metabolism , Adult , Aged , Aged, 80 and over , Dexamethasone/pharmacology , Dose-Response Relationship, Drug , Female , Humans , Hydrocortisone/blood , Male , Sex Factors
18.
Antiviral Res ; 16(4): 295-305, 1991 Dec.
Article in English | MEDLINE | ID: mdl-1810306

ABSTRACT

Ro 31-8959 inhibits the spread of HIV infection and the production of cytopathic effects in cultures of acutely infected cells. IC50 values for these effects are in the range 0.5-6.0 nM and IC90 values are in the range 6.0-30.0 nM. This inhibitor is effective even when added to cultures at a late stage of infection, after syncytia have started to form. Virus antigen, virus particles and virus cytopathic effects can largely be cleared from cultures treated with compound from 3 days until 6 days post infection. In chronically-infected cells, inhibition of virus maturation can be detected after 24 hours' treatment with 10 nM Ro 31-8959. In addition, a significant reduction of the proteolytic processing of p56 to p24 can be demonstrated in these cells with compound at picomolar concentrations. These properties indicate that Ro 31-8959 is highly effective against HIV with the potential to inhibit acute, established acute and chronic infections.


Subject(s)
Antiviral Agents/pharmacology , HIV Infections/drug therapy , HIV Protease Inhibitors , Cell Fusion/drug effects , Cells, Cultured , HIV Antigens/analysis , HIV Protease/pharmacology , Humans , In Vitro Techniques , Saquinavir , Time Factors , Virus Replication/drug effects
19.
Antiviral Res ; 55(2): 307-17, 2002 Aug.
Article in English | MEDLINE | ID: mdl-12103431

ABSTRACT

Oseltamivir carboxylate is a potent and specific inhibitor of influenza A and B neuraminidase (NA). Oseltamivir phosphate, the ethyl ester prodrug of oseltamivir carboxylate, is the first orally active NA inhibitor available for the prophylaxis and treatment of influenza A and B. It offers an improvement over amantadine and rimantadine which are active only against influenza A and rapidly generate resistant virus. The emergence of virus resistant to oseltamivir carboxylate in the treatment of naturally acquired influenza infection is low (about 1%). The types of NA mutation to arise are sub-type specific and largely predicted from in vitro drug selection studies. A substitution of the conserved histidine at position 274 for tyrosine in the NA active site has been selected via site directed mutagenesis, serial passage in culture under drug pressure in H1N1 and during the treatment of experimental H1N1 infection in man. Virus carrying H274Y NA enzyme selected in vivo has reduced sensitivity to oseltamivir carboxylate. The replicative ability in cell culture was reduced up to 3 logs, as was infectivity in animal models of influenza virus infection. Additionally, pathogenicity of the mutant virus is significantly compromised in ferret, compared to the corresponding wild type virus. Virus carrying a H274Y mutation is unlikely to be of clinical consequence in man.


Subject(s)
Acetamides/pharmacology , Antiviral Agents/pharmacology , Influenza A Virus, H1N1 Subtype , Influenza A virus/drug effects , Mutation/drug effects , Neuraminidase/genetics , Acetamides/chemistry , Acetamides/therapeutic use , Amino Acid Substitution , Animals , Antiviral Agents/chemistry , Antiviral Agents/therapeutic use , Body Weight , Cell Line , Disease Models, Animal , Drug Resistance, Viral/genetics , Ferrets , Fever/etiology , Humans , In Vitro Techniques , Inflammation/etiology , Influenza A virus/enzymology , Influenza A virus/genetics , Influenza A virus/pathogenicity , Influenza, Human/drug therapy , Influenza, Human/virology , Mice , Mice, Inbred BALB C , Mutagenesis, Site-Directed , Neuraminidase/antagonists & inhibitors , Neuraminidase/metabolism , Oseltamivir , Sequence Analysis, DNA , Virus Replication
20.
Antiviral Res ; 48(3): 187-96, 2000 Dec.
Article in English | MEDLINE | ID: mdl-11164505

ABSTRACT

Antisense phosphorothioate oligonucleotides (ODN1 0x5 OMe) directed against the E1 start region of human papillomavirus 11 (HPV11) can inhibit papillomavirus induced growth of implanted human foreskin in a mouse xenograft model. Administration of a mismatch control oligonucleotide (ODN9 0x5 OMe), in which guanine was replaced with adenine in the same model, had no effect on papilloma induced growth. However, the apparent antiviral activity of ODN1 0x5 OMe was also shown in a lethal mouse cytomegalovirus (CMV) model, in which the oligonucleotides are not expected to have antisense activity. To understand the mechanisms of action of these oligonucleotides, a mismatch oligonucleotide (ODN61 0x5 OMe) was prepared which retained the CpG motifs of ODN1 0x5 OMe. This was tested in the mouse xenograft model and shown to have moderate inhibitory activity. As a definitive experiment, a comparison was made between the efficacy of the active oligonucleotide ODN1 0x5 OMe against two papilloma viruses HPV11 and HPV40. Both these viruses cause benign genital warts, but differ by four bases in their E1 sequence that was the target for ODN1 0x5 OMe. Papillomavirus induced growth in the mouse xenograft model was inhibited by ODN1 0x5 OMe in both cases, suggesting that oligonucleotide molecules have a non-specific antiviral activity that is not directly related to their antisense sequence.


Subject(s)
DNA-Binding Proteins/drug effects , Oligonucleotides, Antisense/pharmacology , Papillomaviridae/drug effects , Viral Proteins/drug effects , Animals , DNA-Binding Proteins/genetics , Disease Models, Animal , Dose-Response Relationship, Drug , Female , Herpesviridae Infections/virology , Humans , Mice , Mice, Inbred BALB C , Mice, Nude , Muromegalovirus/drug effects , Papillomavirus Infections/virology , Skin Transplantation , Transplantation, Heterologous , Tumor Virus Infections/virology , Viral Proteins/genetics
SELECTION OF CITATIONS
SEARCH DETAIL